Review
Copyright ©The Author(s) 2016.
World J Hepatol. Nov 18, 2016; 8(32): 1354-1369
Published online Nov 18, 2016. doi: 10.4254/wjh.v8.i32.1354
Figure 2
Figure 2 Enhanced lipopolysaccharide/toll-like receptors 4 signaling in chronic liver diseases. Induction of anti-viral responses, inflammation, steatosis, fibrosis, and hepatocarcinoma via LPS/TLR4 signaling alongside hepatic fibrosis mediated portal hypertension which further increases bacterial overgrowth and intestinal permeability, creating a positive feedback process. TLR4: Toll-like receptors 4; LPS: Lipopolysaccharide.